Rectal Neoplasms
Conditions
Keywords
Cancer, Colorectal cancer, Biological Specimen Banks
Brief summary
A Clinical and Biological Database will provide to the scientific community a collection of blood and tissues with clinical data to improve knowledge about cancer and help to develope new cancer treatments. This database is specific to Rectum Cancer.
Detailed description
In France, colorectal cancer is the second major cause of cancer-related death with 17 000 cases per year. Rectal carcinoma represents 40% of colorectal cancers. Locally advanced rectal carcinoma raises the issue of both the oncological control, local and general, and the therapeutic morbidity. Currently, pre-operative radiochemotherapy associated with radical proctectomy (TME) is the standard treatment. Radiochemotherapy improves the local control but with enhanced postoperative morbidity and poor functional results. Moreover, some patients have no downstaging (around 1/3) and the metastatic risk remains about 30%. Then, compliance to adjuvant chemotherapy is generally poor after radical proctectomy. Tumor response to preoperative treatment is the major prognostic factor which reveals tumor aggressiveness. Nevertheless, at present, there are no predictive markers of tumor response. Progresses in rectal cancer management are related to sharing biological and clinical resources with scientific community. A clinical and biological collection will allow to : * develop research programs on predictive markers to pre-operative radiochemotherapy or prognostics factors to disease recurrence * optimize diagnostic and follow-up tests * develop new biomarkers to improve patient's therapeutic management In this context, the Montpellier Cancer Institute (ICM) decided to initiate a biological collection biomedical research dedicated to the tissular and blood samples of patients with colorectal cancer.
Interventions
OTHERBiological collection
Blood samples are collected at different times : * Before any treatment * After pre-operative radiochemotherapy and before surgery (if applicable)
Sponsors
Institut du Cancer de Montpellier - Val d'Aurelle
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient treated at the Montpellier Cancer Institute, whatever the treatment received (systemic cancer treatment or radiotherapy or surgery) * Age \> 18 years * Signed informed consent
Exclusion criteria
* Patient not affiliated to Social Protection system * Patient unable to understand or comply with study instructions or requirements for psychological, family, social or geographical reasons * Patient under guardianship
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients who gave their consent to participate in the study | Until the study completion : 66 months | The proportion of patients who consent to participate in the study among the screened patients |
Countries
France
Contacts
Primary ContactAurore MOUSSION
Outcome results
None listed